179 related articles for article (PubMed ID: 25413383)
1. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
2. The new oral anticoagulants and the future of haemostasis laboratory testing.
Favaloro EJ; Lippi G
Biochem Med (Zagreb); 2012; 22(3):329-41. PubMed ID: 23092064
[TBL] [Abstract][Full Text] [Related]
3. Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation.
Henskens YMC; Gulpen AJW; van Oerle R; Wetzels R; Verhezen P; Spronk H; Schalla S; Crijns HJ; Ten Cate H; Ten Cate-Hoek A
Thromb J; 2018; 16():3. PubMed ID: 29434525
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs.
Fadraersada J; Alva-Gallegos R; Skořepa P; Musil F; Javorská L; Matoušová K; Krčmová LK; Paclíková M; Carazo A; Blaha V; Mladěnka P
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4461-4470. PubMed ID: 38112731
[TBL] [Abstract][Full Text] [Related]
5. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: Results from DRIVING study.
de Fautereau-Vassel A; Mokhtarian A; Mangenot M; Krekounian O; Kousignian I; Delavenne X; Curis E; Gouin-Thibault I; Siguret V
Int J Lab Hematol; 2024 Feb; 46(1):120-127. PubMed ID: 37710085
[TBL] [Abstract][Full Text] [Related]
6. Preoperative evaluation of coagulation status in neuromodulation patients.
Hadanny A; Olmsted ZT; Marchese AM; Kroll K; Figueroa C; Tagney T; Tram J; DiMarzio M; Khazen O; Mitchell D; Cangero T; Sukul V; Pilitsis JG
J Neurosurg; 2022 Jul; 137(1):192-198. PubMed ID: 34826810
[TBL] [Abstract][Full Text] [Related]
7. On the hyphen.
Schrewe B
CMAJ; 2024 Jun; 196(21):E732-E733. PubMed ID: 38830677
[No Abstract] [Full Text] [Related]
8. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
Nielsen PB; Lane DA; Rasmussen LH; Lip GY; Larsen TB
Clin Res Cardiol; 2015 May; 104(5):418-29. PubMed ID: 25416564
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
[TBL] [Abstract][Full Text] [Related]
10. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.
Frost C; Song Y; Barrett YC; Wang J; Pursley J; Boyd RA; LaCreta F
Clin Pharmacol; 2014; 6():179-87. PubMed ID: 25419161
[TBL] [Abstract][Full Text] [Related]
11. Monitoring and reversal strategies for new oral anticoagulants.
Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
[TBL] [Abstract][Full Text] [Related]
12. Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.
Burghaus R; Coboeken K; Gaub T; Niederalt C; Sensse A; Siegmund HU; Weiss W; Mueck W; Tanigawa T; Lippert J
Front Physiol; 2014; 5():417. PubMed ID: 25426077
[TBL] [Abstract][Full Text] [Related]
13. Is Dabigatran As Effective As Warfarin on Cardiac Thrombus in a Patient With Atrial Fibrillation? A Challenging Question.
Sunbul M; Cincin A; Mammadov C; Mutlu B
Am J Ther; 2016; 23(3):e974-6. PubMed ID: 25415546
[TBL] [Abstract][Full Text] [Related]
14. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
15. Strategies for urgent reversal of target-specific oral anticoagulants.
Davis EM; Uhlmeyer EM; Schmidt DP; Schardt GL
Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan.
Okata T; Toyoda K; Okamoto A; Miyata T; Nagatsuka K; Minematsu K
PLoS One; 2014; 9(11):e113641. PubMed ID: 25479967
[TBL] [Abstract][Full Text] [Related]
17. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal.
Lip GY; Wang KL; Chiang CE
Int J Cardiol; 2015 Feb; 180():246-54. PubMed ID: 25463377
[TBL] [Abstract][Full Text] [Related]
18. Comparison of methods to determine rivaroxaban anti-factor Xa activity.
Rathbun S; Tafur A; Grant R; Esmon N; Mauer K; Marlar RA
Thromb Res; 2015 Feb; 135(2):394-7. PubMed ID: 25476589
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
[TBL] [Abstract][Full Text] [Related]
20. RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy.
Calkins H; Gerstenfeld EP; Schilling R; Verma A; Willems S;
Am J Cardiol; 2015 Jan; 115(1):154-5. PubMed ID: 25456859
[No Abstract] [Full Text] [Related]
[Next] [New Search]
